- ►diabetesjournals.org E Mannucci, A Ognibene, F Cremasco, G Bardini, A … - Diabetes Care, 2001 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 10 obese nondiabetic male patients were
studied before and after a 14-day treatment with 2,550 mg/day metformin and were compared
with 10 untreated obese control subjects. On days 0 and 15, leptin and GLP-1(7–36) ... Cited by 105 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org [PDF] SA Hinke, CHS McIntosh, T Hoffmann, K Kühn- … - Diabetes Care, 2002 - Am Diabetes Assoc The provision of diabetes care has shifted from the specialist to the generalist in primary care
practice. Evidence suggests utilization of nonphy- sician providers in conjunction with phy-
sician-directed protocols improves glycemic control (1). The purpose of this study was to ... Cited by 28 - Related articles - BL Direct - All 5 versions
- ►cyclicamp.ca [PDF] SA Hinke, K Kühn-Wache, T Hoffmann, RA … - … and Biophysical Research …, 2002 - Elsevier There is current interest in the use of inhibitors of dipeptidyl peptidase IV (DP IV) as therapeutic
agents to normalize glycemic excursions in type 2 diabetic patients. Data indicating that metformin
increases the circulating amount of active glucagon-like peptide-1 (GLP-1) in obese ... Cited by 42 - Related articles - BL Direct - All 5 versions
[CITATION] Single dose treatment of diabetic patients by the DPIV inhibitor P32/98
N Yasuda, T Inoue, T Nagakura, K Yamazaki, K … - … and Biophysical Research …, 2002 - Elsevier Metformin was reported to increase plasma active glucagon-like peptide-1 (GLP-1) in
humans. There are two possible mechanisms for this effect: (1) metformin inhibits dipeptidyl peptidase
IV (DPPIV), an enzyme degrading GLP-1, and (2) metformin enhances GLP-1 secretion. ... Cited by 43 - Related articles - BL Direct - All 6 versions
JR Lindsay, NA Duffy, AM McKillop, J Ardill, … - Diabetic …, 2005 - interscience.wiley.com Aims Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important
insulinotropic hormones that enhance the insulin secretory response to feeding. Their potential
for treating Type 2 diabetes is limited by short biological half-life owing to degradation by ... Cited by 44 - Related articles - All 5 versions
JM Lenhard, DK Croom, DT Minnick - Biochemical and Biophysical Research …, 2004 - Elsevier Dipeptidyl peptidase-IV (DPP-IV) regulates metabolism by degrading incretins involved in nutritional
regulation. Metformin and pioglitazone improve insulin sensitivity whereas glyburide promotes
insulin secretion. Zucker diabetic rats were treated with these antidiabetic agents for 2 ... Cited by 21 - Related articles - All 4 versions
GS Meneilly, CHS McIntosh, RA Pederson, JF … - Diabetes Care, 2001 - Am Diabetes Assoc An important cause of elevated glucose levels in elderly patients with diabetes is an alteration
in non–insulin-mediated glucose uptake (NIMGU). Glucagon-like peptide 1 (GLP-1) is an intestinal
insulinotropic hormone. It has been proposed that this hormone also lowers glucose ... Cited by 61 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org M Zander, M Taskiran, MB Toft-Nielsen, S Madsbad … - Diabetes Care, 2001 - Am Diabetes Assoc OBJECTIVE—The incretin hormone glucagon-like peptide-1 (GLP-1) reduces plasma glucose
in type 2 diabetic patients by stimulating insulin secretion and inhibiting glucagon secretion.
The biguanide metformin is believed to lower plasma glucose without affecting insulin ... Cited by 47 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org R Lupi, S Del Guerra, V Fierabracci, L Marselli, M … - Diabetes, 2002 - Am Diabetes Assoc Human pancreatic islets from eight donors were incubated for 48 h in the presence of 2.0
mmol/l free fatty acid (FFA) (oleate to palmitate, 2 to 1). Insulin secretion was then assessed in
response to glucose (16.7 mmol/l), arginine (20 mmol/l), and glyburide (200 µmol/l) ... Cited by 80 - Related articles - BL Direct - All 5 versions
